Healios
Healios is dedicated to expanding the options for patients to 'live' through regenerative medicine, aiming to deliver new treatments and hope to patients worldwide. The company focuses on research, development, and manufacturing of cell therapy and regenerative medicine products, with a mission to foster a 'Life Explosion' that enriches lives globally. Additionally, Healios is advancing the use of Universal Donor Cells (UDC) for next-generation cancer immunotherapy, ophthalmology, and organ progenitors, promoting in-house development of regenerative medicines and collaborations with research institutions to develop new treatments.
Industries
Nr. of Employees
medium (51-250)
Healios
Hibiya Mitsui Tower 12F, WORK STYLING, 1-1-2 Yurakucho, Chiyoda-ku, Tokyo 100-0006, Japan
Patents
Apparatus and method for cryostorage and manipulation of a plurality of container units
US-11566834-B2
View Details
Apparatus and method for cryostorage and manipulation of a plurality of container units
US-11566834-B2
View DetailsProducts
Allogeneic multipotent somatic stem cell therapeutic (systemic IV)
A cryopreserved allogeneic multipotent stem cell product developed for intravenous administration to modulate acute inflammation and support tissue protection/repair in indications such as ischemic stroke, ARDS and trauma.
iPSC-derived retinal pigment epithelium (RPE) cell therapy
A cell-replacement therapy consisting of iPSC-derived RPE cells or RPE cell sheets intended to restore or maintain retinal function in RPE-defect and age-related macular degeneration indications.
iPSC-derived gene-edited NK cell immunotherapy
An engineered iPSC-derived NK cell product with gene edits to enhance anti-cancer activity, intended for immuno-oncology applications against solid tumors.
Vascularized liver organ primordia (3D organ constructs)
Three-dimensional, vascularized organ primordia produced from precursor cells designed for transplantation to restore or augment liver function in preclinical models of liver failure and metabolic disease.
Allogeneic multipotent somatic stem cell therapeutic (systemic IV)
A cryopreserved allogeneic multipotent stem cell product developed for intravenous administration to modulate acute inflammation and support tissue protection/repair in indications such as ischemic stroke, ARDS and trauma.
iPSC-derived retinal pigment epithelium (RPE) cell therapy
A cell-replacement therapy consisting of iPSC-derived RPE cells or RPE cell sheets intended to restore or maintain retinal function in RPE-defect and age-related macular degeneration indications.
iPSC-derived gene-edited NK cell immunotherapy
An engineered iPSC-derived NK cell product with gene edits to enhance anti-cancer activity, intended for immuno-oncology applications against solid tumors.
Vascularized liver organ primordia (3D organ constructs)
Three-dimensional, vascularized organ primordia produced from precursor cells designed for transplantation to restore or augment liver function in preclinical models of liver failure and metabolic disease.
Services
Contract development and GMP manufacturing support for cell therapy products provided via a dedicated subsidiary model.
Design, registration and conduct of randomized multicenter clinical trials (Phase II/III), including data management and analysis support for cell therapy products.
Formation and management of academic and industry partnerships, licensing transactions and joint ventures to advance translational programs and access external IP.
Operation of fund and fund-management entities to support investments and ecosystem development for regenerative medicine startups and technologies.
Contract development and GMP manufacturing support for cell therapy products provided via a dedicated subsidiary model.
Design, registration and conduct of randomized multicenter clinical trials (Phase II/III), including data management and analysis support for cell therapy products.
Formation and management of academic and industry partnerships, licensing transactions and joint ventures to advance translational programs and access external IP.
Operation of fund and fund-management entities to support investments and ecosystem development for regenerative medicine startups and technologies.
Expertise Areas
- Universal-donor iPSC platform development
- Gene editing for immune modulation and safety
- iPSC-derived immune effector cell engineering
- Somatic (multipotent) stem cell therapeutics
Key Technologies
- Induced pluripotent stem cell (iPSC) platforms
- Gene editing of cellular genomes
- Immune-evasive universal-donor iPSC lines
- iPSC-derived natural killer (NK) cell engineering
News & Updates
CEO Tadahisa Kagimoto will appear on Radio NIKKEI's 'Ohayo Market' to discuss the company's developments.
A video interview with CEO Kagimoto and investor 'Hasshan' was published on FISCO TV.
A corporate research report by FISCO was published regarding Healios.
CEO Kagimoto was interviewed on Biotech TV about the company's activities.
A briefing video on ARDS research held on April 9, 2025.
A detailed report issued by FISCO about Healios.
CEO Tadahisa Kagimoto will appear on Radio NIKKEI's 'Ohayo Market' to discuss the company's developments.
A video interview with CEO Kagimoto and investor 'Hasshan' was published on FISCO TV.
A corporate research report by FISCO was published regarding Healios.
CEO Kagimoto was interviewed on Biotech TV about the company's activities.
A briefing video on ARDS research held on April 9, 2025.
A detailed report issued by FISCO about Healios.